ClinicalTrials.gg
CompletedNCT07655791Updated Oct 20, 2026

Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis

A Phase 4 interventional study of Nicotinamide 1000 mg in Sepsis - to Reduce Mortality in the Intensive Care Unit, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Ain Shams University · Phase 4, Interventional, and Supportive care

How we know

Updated Oct 20, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Sepsis by Ain Shams University — 8 open to participants now, 10 under way, none of them phase 3. Sepsis · Ain Shams University.

Enrollment
8th of 11
60 · median 72
Started
2026
with 2 others
Phase 4
3 of 30
none open now
Registered
27th of 30
by date

Among the 30 studies in Sepsis by Ain Shams University, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 4, and was the 27th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

8 of the 30 studies in Sepsis by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Sepsis by Ain Shams University, or all of them as a file.
02

Study summary

Sepsis is a severe, life-threatening condition caused by an abnormal host response to infection, which includes systemic inflammation, oxidative stress, and increasing organ dysfunction. It is frequently associated with bacterial, viral, fungal, or parasite infections, as well as non-infectious illnesses like trauma and pancreatitis. It remains a primary cause of mortality in hospitals, with rates nearing 40% in severely ill patients. pathophysiological, excessive cytokine release (e.g., TNFα, IL-6, IL-1β) and reactive oxygen/nitrogen species lead to mitochondrial injury, immunosuppression, and multiple organ failure. Sepsis diagnosis is guided byNEWS2 \& a SOFA score ≥2, hypotension, and elevated lactate, while worsening SOFA scores predict poor outcomes. Standard management focusses on early antibiotic therapy, fluid resuscitation, and vasoactive support. Standard anti-inflammatory methods using steroidal or non-steroidal medicines may show little efficacy to improve the patient's clinical outcomes. Adjunctive antioxidant therapies, including vitamins C and E, NAC, and melatonin, have demonstrated reductions in oxidative stress and organ dysfunction. Nicotinamide (NAM) (vitamin B3), a precursor of NAD+/NADP+ critical for energy metabolism and cellular repair, has emerged as a potential therapeutic candidate due to its ability to attenuate cytokine production, modulate immune responses, and mitigate oxidative damage. Usual dose of NAM (500mg-1500mg per day) is generally safe. A dose of 1000 mg was found to be safe and effective in reducing the circulating inflammatory cytokines showing a good profile as an anti-inflammatory adjunct therapy. Higher than usual NAM dose can increase the likelihood of adverse effects, such as diarrhea, increased liver enzymes (rarely occurring at doses exceeding 3 grams per day), symptoms of thrombocytopenia (including increased bruising and bleeding), and stomach upset.

Since the role of NAM as adjunct therapy in sepsis management is not yet established, further large-scale clinical studies are recommended to establish its efficacy and safety in sepsis management.

The aim of our study is to evaluate the efficacy and safety of the addition of Nicotinamide (1000mg oral tablet) as an adjunct therapy to improve the outcome of septic patients.

Read the detailed description

Sepsis is a life-threatening medical illness caused by the body's response to an infection, resulting in extensive inflammation. This inflammation can cause a series of changes in the body, leading to restricted blood flow to key organs, causing organ failure and eventually death. Sepsis can be caused by bacteria, viruses, fungi, or parasites, or it can develop due to noninfectious intra-abdominal causes, including severe trauma, pneumonia, pancreatitis, and urinary system infection. Despite advances in medical treatments, sepsis remains a major cause of death globally among hospitalized patients because of its complications. According to reports, Hospital mortality rates were 26% for hospital-wide sepsis and 40% for ICU sepsis. Sepsis was more common in the United States among men, non-white individuals, and the elderly (60 years and older) than among women and white persons.

Severe sepsis is characterized by one or more end-organ failures, while septic shock is characterized by hemodynamic instability despite intravascular volume replacement. The overwhelming immune response and the altered balance between pro-inflammatory and anti-inflammatory mediators contribute to the development of sepsis, making it particularly challenging to treat.

Some possible complications of sepsis include Acute/chronic renal injury, Mesenteric ischemia, Acute liver failure, Myocardial dysfunction, and Multiple organ failure. Previous studies showed that sepsis can cause the disturbance of immunological homeostasis, leading to immunosuppression in sepsis.

The SOFA (Sequential Organ Failure Assessment) score is currently advised for diagnosing both sepsis and septic shock. A diagnosis of sepsis is confirmed in the case of a (SOFA) score ≥ 2. The SOFA system is a simple technique that detects organ failure or dysfunction due to sepsis. Daily, the SOFA scoring scale allocates from 1 to 4 points for each of the following six organ systems, according to the level of dysfunction: The respiratory, circulatory, renal, hematological, hepatic, and central nervous systems. Sepsis is presented by a rise of two or more points in the SOFA score. Moreover, the SOFA score could be a method to assess morbidity in intensive care unit (ICU) sepsis patients.

Cytokines are essential for the effective functioning of critical host immune systems because they regulate the body's reactions to infection, immunological responses, inflammation, and trauma. Modifying the cytokine response is an important aspect of therapy for many severe inflammatory disorders. In septic patients, it has been demonstrated that TNFα, IL-6, and IL-1β correspond with the severity of the disease and its outcome.

Oxidative stress (OS) damage plays a role in the pathogenesis of major disorders such as sepsis-induced multiple organ failure (MOF). Studies in animal models and septic shock patients have revealed an imbalance between the formation of reactive oxygen (ROS) and nitrogen (RNS) species and antioxidant defenses. ROS are produced by phagocytic cells, enzymes such as NADPH oxidase, xanthine oxidase, and iNOS, and enhanced inflammatory mediators via NFκB activation. OS-induced mitochondrial damage is part of the pathogenesis of MOF, subsequent sepsis.

To diagnose sepsis patients: SOFA score ≥ 2, mean arterial pressure (MAP) \< 65 mmHg, and serum lactate level ≥ 2 mmol/L. Blood should be collected before initiating antibiotics to guide therapy and help determine the source of infection.

Effective sepsis management requires a combination of rapid interventions and supportive care. It involves different pathophysiological aspects, encompassing empirical antimicrobial treatment (which is promptly administered after microbial tests), fluid (crystalloids) replacement (to be established according to fluid tolerance and fluid responsiveness), and vasoactive agents (e.g., norepinephrine). Administering the appropriate medications on time has been linked to higher survival rates. Supportive care and adjuvant therapy, such as the use of corticosteroids, blood purification techniques, and immunomodulatory therapies, are still under investigation.

The inflammatory response in sepsis has played a significant role, and so, Standard therapy includes the use of steroidal and non-steroidal anti-inflammatory medicines, which have resulted in poor outcomes. Currently, antioxidant therapy in septic shock patients has been demonstrated to be effective in lowering Oxidative Stress (OS) indicators. Similarly, it was discovered that adding antioxidant therapy to the standard therapy in septic shock enhances total antioxidant capacity and reduces OS.

Many therapeutic strategies have focused on controlling the inflammatory response and managing oxidative stress, both of which are central to sepsis pathogenesis. Antioxidants and anti-inflammatory medications aim to counteract the overproduction of reactive oxygen species (ROS) and inflammatory cytokines, potentially reducing damage to tissues and organs. However, the complexity of sepsis, with its multifactorial nature and diverse responses among patients, continues to present challenges for developing more effective treatments.

Patients who receive antioxidants such as vitamin C, vitamin E, NAC, or MT in addition to traditional therapy demonstrate lower levels of pro-inflammatory cytokines and enhanced regulatory function in IL-2, IL-12, and IFN. The antioxidant capacity has improved, and indicators of oxidative stress have decreased, indicating that organ damage has reduced as determined by the SOFA score.

Nicotinamide (or nicotinamide) is a form of vitamin B3 that is often confused with its precursor nicotinic acid (or niacin) . Nicotinamide (NAM; niacin), nicotinic acid (niacin), and NAM riboside (NR) are the three vitamins that make up the components of the water-soluble vitamin B3 family. Nicotinamide is a precursor to two essential cofactors in cellular metabolism: Nicotinamide adenine dinucleotide (NAD) and its phosphate form, NADP. Nicotinamide adenine dinucleotide (NAD+) coenzymes are the primary regulators of cellular metabolism. While metabolic stress and age-related diseases can disrupt the NAD+ system, NAD is essential for several biological functions, such as DNA repair, energy synthesis, and cellular stress mechanisms.

Previous research suggests that NAM can effectively reduce cytokine release and inflammatory cell chemotaxis in skin disorders. Research indicates that NAM can reduce the number of inflammatory macrophages in chemically induced skin cancer. NAM has been shown to inhibit the secretion of cytokines and the chemotaxis of inflammatory cells in inflammatory skin diseases. This suggests that NAM might play a role in modulating immune responses, especially in conditions where excessive inflammation leads to tissue damage, like in psoriasis or eczema.

NAM may have therapeutic potential as a modulator of cytokine effects in inflammatory diseases since it significantly inhibits the proinflammatory cytokine response of IL-1β, IL-6, IL-8, and TNFα after endotoxin stimulation of human whole blood.

In general, Nicotinamide has fewer potential negative effects than other niacin supplements. There are expected mild side effects of NAM as (gastrointestinal upset, Headache, dizziness and Fatigue). However, a medication safety trial reported that consuming larger amounts of Nicotinamide than usual can increase the likelihood of adverse effects, such as diarrhea, increased liver enzymes (rarely occurring at doses exceeding 3 grams per day), symptoms of thrombocytopenia (including increased bruising and bleeding), which is a rare side effect. The severity of nicotinamide-induced adverse effects determines how they are managed. Antacids such as calcium carbonate, probiotics, or taking the dose with food can help ease gastrointestinal distress. Headaches can be treated with basic analgesics such as paracetamol or ibuprofen if not contraindicated. Although dizziness normally requires just supportive care, such as appropriate fluids or oral rehydration, it may be needed. Fatigue has no specific pharmacologic treatment, but improving sleep, staying hydrated, and taking a non-excessive B-complex supplement may assist. Diarrhea caused by large doses can be treated with oral rehydration salts and, if necessary, short-term loperamide, as well as lowering the nicotinamide dose.

Nicotinamide riboside (NR) increases NAD+ + levels and may help lower inflammation, even if metabolic stress and age-related disorders dysregulate the NAD+ + system. A previous Study Proves that NR markedly reduced the gene expression of IL-6 and IL-18 in peripheral blood mononuclear cells Moreover, it was found to reduce the incidence of RRT/death and improve the creatinine outcome in individuals with severe COVID-19-related AKI. Larger randomized trials are required to determine a causal link Given the high morbidity and mortality associated with septic patient, incorporating NAM as an adjunct to standard sepsis care could offer a novel therapeutic approach to improving survival and reducing long-term complications.

03

Conditions studied

  • Sepsis - to Reduce Mortality in the Intensive Care Unit

Browse trials for

Keywords

  • Sepsis
  • IL-6
  • NF-kB
  • anti-inflammatory
  • Nicotinamide
  • Mortality
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients older than 18 years of any gender who were admitted to the intensive care unit
  • Diagnosed as sepsis patient with the Sequential Organ Failure Assessment (SOFA) Score described as an Increase in SOFA score ≥2 points due to infection.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Patients who had already been taking antioxidant supplements before recruiting.
  • Patient with or reported allergies to Nicotinamide.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • No intervention
    Control Group

    30 Patients will receive the treatment alone according to the hospital management protocol

  • Active comparator
    Interventional Group

    30 Patients will receive 1000mg oral Nicotinamide tablets as an adjunct therapy to the treatment provided to the sepsis patients according to the hospital management protocol.

    Drug: Nicotinamide 1000 mg

Interventions

06

What researchers measure

Primary outcomes

  1. The Change in SOFA Score

    The SOFA (Sequential Organ Failure Assessment) score is a crucial ICU tool that quantifies organ dysfunction with score totaling 0-24, the higher score the worser Outcome

    Time frame: 7 days of receiving treatment.

Secondary outcomes

  1. Change in IL-6 levels in serum

    serum IL-6 level change will be calculated by subtracting the IL-6 level in Day 7 minus Baseline IL-6 level

    Time frame: At the 7th day of follow up

  2. Change in NF-kB in serum

    serum NF-kB level change will be calculated by subtracting the IL-6 level in Day 7 minus Baseline IL-6 level

    Time frame: At 7th day of follow up

  3. Length of ICU stay (days)

    Length of ICU stay measured in days from ICU admission until ICU discharge or death, obtained from patient medical records.

    Time frame: From ICU admission until ICU discharge or death, up to 28 days

  4. 28 day Mortality

    to determine the mortality rate

    Time frame: At the 28th day of follow up

  5. Length of hospital stay (days)

    Change in length of hospital stay (days) measured from hospital admission to hospital discharge and obtained from patient medical records.

    Time frame: From hospital admission until discharge, up to 28 days

  6. Assess the septic patients Mortality rate.

    Assess effect of Nicotinamide on change of the Mortality rate in septic patient.

    Time frame: 28 mortality day

07

Study locations

1 site
  • El Demardash Hospital
    Cairo, Egypt
08

References and documents

Publications

  • Raines NH, Ganatra S, Nissaisorakarn P, Pandit A, Morales A, Asnani A, Sadrolashrafi M, Maheshwari R, Patel R, Bang V, Shreyder K, Brar S, Singh A, Dani SS, Knapp S, Poyan Mehr A, Brown RS, Zeidel ML, Bhargava R, Schlondorff J, Steinman TI, Mukamal KJ, Parikh SM. Niacinamide May Be Associated with Improved Outcomes in COVID-19-Related Acute Kidney Injury: An Observational Study. Kidney360. 2020 Nov 20;2(1):33-41. doi: 10.34067/KID.0006452020. eCollection 2021 Jan 28. PubMed 35368823 ↗
  • Hong G, Zheng D, Zhang L, Ni R, Wang G, Fan GC, Lu Z, Peng T. Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis. Free Radic Biol Med. 2018 Aug 1;123:125-137. doi: 10.1016/j.freeradbiomed.2018.05.073. Epub 2018 May 24. PubMed 29803807 ↗
  • Dolopikou CF, Kourtzidis IA, Margaritelis NV, Vrabas IS, Koidou I, Kyparos A, Theodorou AA, Paschalis V, Nikolaidis MG. Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study. Eur J Nutr. 2020 Mar;59(2):505-515. doi: 10.1007/s00394-019-01919-4. Epub 2019 Feb 6. PubMed 30725213 ↗
  • Zhang Q, Li J, Zhong H, Xu Y. The mechanism of nicotinamide on reducing acute lung injury by inhibiting MAPK and NF-kappaB signal pathway. Mol Med. 2021 Sep 20;27(1):115. doi: 10.1186/s10020-021-00376-2. PubMed 34544355 ↗
  • Camillo L, Zavattaro E, Savoia P. Nicotinamide: A Multifaceted Molecule in Skin Health and Beyond. Medicina (Kaunas). 2025 Feb 1;61(2):254. doi: 10.3390/medicina61020254. PubMed 40005371 ↗
  • Snaidr VA, Damian DL, Halliday GM. Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. Exp Dermatol. 2019 Feb;28 Suppl 1:15-22. doi: 10.1111/exd.13819. PubMed 30698874 ↗
  • Fontecha-Barriuso M, Lopez-Diaz AM, Carriazo S, Ortiz A, Sanz AB. Nicotinamide and acute kidney injury. Clin Kidney J. 2021 Sep 23;14(12):2453-2462. doi: 10.1093/ckj/sfab173. eCollection 2021 Dec. PubMed 34950458 ↗
  • Huber R, Wong A. Nicotinamide: An Update and Review of Safety & Differences from Niacin. Skin Therapy Lett. 2020 Nov;25(5):7-11. PubMed 33196157 ↗
  • Perez-Torres I, Aisa-Alvarez A, Casarez-Alvarado S, Borrayo G, Marquez-Velasco R, Guarner-Lans V, Manzano-Pech L, Cruz-Soto R, Gonzalez-Marcos O, Fuentevilla-Alvarez G, Gamboa R, Saucedo-Orozco H, Franco-Granillo J, Soto ME. Impact of Treatment with Antioxidants as an Adjuvant to Standard Therapy in Patients with Septic Shock: Analysis of the Correlation between Cytokine Storm and Oxidative Stress and Therapeutic Effects. Int J Mol Sci. 2023 Nov 22;24(23):16610. doi: 10.3390/ijms242316610. PubMed 38068931 ↗
  • Aisa-Alvarez A, Soto ME, Guarner-Lans V, Camarena-Alejo G, Franco-Granillo J, Martinez-Rodriguez EA, Gamboa Avila R, Manzano Pech L, Perez-Torres I. Usefulness of Antioxidants as Adjuvant Therapy for Septic Shock: A Randomized Clinical Trial. Medicina (Kaunas). 2020 Nov 17;56(11):619. doi: 10.3390/medicina56110619. PubMed 33213070 ↗
  • Martinez ML, Plata-Menchaca EP, Ruiz-Rodriguez JC, Ferrer R. An approach to antibiotic treatment in patients with sepsis. J Thorac Dis. 2020 Mar;12(3):1007-1021. doi: 10.21037/jtd.2020.01.47. PubMed 32274170 ↗
  • Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003 Jan;131(1):48-52. doi: 10.1046/j.1365-2249.2003.02031.x. PubMed 12519385 ↗
  • Minne L, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Crit Care. 2008;12(6):R161. doi: 10.1186/cc7160. Epub 2008 Dec 17. PubMed 19091120 ↗
  • Rello J, Valenzuela-Sanchez F, Ruiz-Rodriguez M, Moyano S. Sepsis: A Review of Advances in Management. Adv Ther. 2017 Nov;34(11):2393-2411. doi: 10.1007/s12325-017-0622-8. Epub 2017 Oct 11. PubMed 29022217 ↗
  • Marques A, Torre C, Pinto R, Sepodes B, Rocha J. Treatment Advances in Sepsis and Septic Shock: Modulating Pro- and Anti-Inflammatory Mechanisms. J Clin Med. 2023 Apr 15;12(8):2892. doi: 10.3390/jcm12082892. PubMed 37109229 ↗
  • Guarino M, Perna B, Cesaro AE, Maritati M, Spampinato MD, Contini C, De Giorgio R. 2023 Update on Sepsis and Septic Shock in Adult Patients: Management in the Emergency Department. J Clin Med. 2023 Apr 28;12(9):3188. doi: 10.3390/jcm12093188. PubMed 37176628 ↗
  • Liu D, Huang SY, Sun JH, Zhang HC, Cai QL, Gao C, Li L, Cao J, Xu F, Zhou Y, Guan CX, Jin SW, Deng J, Fang XM, Jiang JX, Zeng L. Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options. Mil Med Res. 2022 Oct 9;9(1):56. doi: 10.1186/s40779-022-00422-y. PubMed 36209190 ↗
  • Peivandi Yazdi A, Razavi M, Sheikh S, Boroumand N, Salehi M, Hashemy SI. Clinical Trial Assessment of Intermittent and Continuous Infusion Dose of N-Acetylcysteine on Redox Status of the Body in Patients with Sepsis Admitted to the ICU. J Intensive Care Med. 2020 Dec;35(12):1383-1388. doi: 10.1177/0885066618823152. Epub 2019 Jan 13. PubMed 30636490 ↗
  • Rivers EP, Jaehne AK, Eichhorn-Wharry L, Brown S, Amponsah D. Fluid therapy in septic shock. Curr Opin Crit Care. 2010 Aug;16(4):297-308. doi: 10.1097/MCC.0b013e32833be8b3. PubMed 20601867 ↗
  • Prauchner CA. Oxidative stress in sepsis: Pathophysiological implications justifying antioxidant co-therapy. Burns. 2017 May;43(3):471-485. doi: 10.1016/j.burns.2016.09.023. Epub 2016 Dec 27. PubMed 28034666 ↗
  • Lei S, Li X, Zhao H, Xie Y, Li J. Prevalence of sepsis among adults in China: A systematic review and meta-analysis. Front Public Health. 2022 Oct 11;10:977094. doi: 10.3389/fpubh.2022.977094. eCollection 2022. PubMed 36304237 ↗
  • Woznica EA, Inglot M, Woznica RK, Lysenko L. Liver dysfunction in sepsis. Adv Clin Exp Med. 2018 Apr;27(4):547-551. doi: 10.17219/acem/68363. PubMed 29558045 ↗
  • Moschopoulos CD, Dimopoulou D, Dimopoulou A, Dimopoulou K, Protopapas K, Zavras N, Tsiodras S, Kotanidou A, Fragkou PC. New Insights into the Fluid Management in Patients with Septic Shock. Medicina (Kaunas). 2023 May 29;59(6):1047. doi: 10.3390/medicina59061047. PubMed 37374251 ↗
  • Gyawali B, Ramakrishna K, Dhamoon AS. Sepsis: The evolution in definition, pathophysiology, and management. SAGE Open Med. 2019 Mar 21;7:2050312119835043. doi: 10.1177/2050312119835043. eCollection 2019. PubMed 30915218 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Sep 2026, 5 months.

Of 65 non-industry phase 4 interventional studies under Sepsis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's 5 months is below that.

Counting every sponsor, half of 66 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Jul 2026 → Mar 2026, primary completion Oct 2026 → Sep 2026 and completion Jan 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Jun 18, 2026
StartActual
Mar 28, 2026was Jul 2026
Primary completionActual
Sep 26, 2026was Oct 2026
CompletionActual
Sep 26, 2026was Jan 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 20, 2026
Start date
Jul 1, 2026→Mar 28, 2026 (actual)
Oct 20, 2026
Primary completion
Oct 1, 2026→Sep 26, 2026 (actual)
Oct 20, 2026
Study completion
Jan 1, 2027→Sep 26, 2026 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Not yet recruiting→Completed
    Start date Jul 1, 2026→Mar 28, 2026 (now actual)
    Primary completion Oct 1, 2026→Sep 26, 2026 (now actual)
    Study completion Jan 1, 2027→Sep 26, 2026 (now actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07655791
Collaborators
Egyptian Chinese University
Responsible party
Basma Ahmed ABD EL Sattar Amin (Teaching Assistant , Pharmacy Practice, Egyptian Chinese University, Ain Shams University) — Principal investigator
First posted
Jun 18, 2026
Start date
Mar 28, 2026
Primary completion
Sep 26, 2026
Completion
Sep 26, 2026
Last update
Oct 20, 2026

Study contacts

Sarah Farid, PhD
study director · Clinical Pharmacy department Faculty of Pharmacy AIn SHams University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Niacinamide

Start the discussion